Exelixis | EXEL - Pre Tax Profit


Exelixis reported $267.69M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Amgen USD 2.08B 570M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
Bayer EUR 2.99B 6.36B Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY 25.28B 33.22B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Exelixis USD 267.69M 15M Mar/2026
Genmab DKK 295M 221M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Moderna USD -1.33B 535M Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Sanofi EUR 2B 3.16B Mar/2026
Takeda JPY 162.72B 215.2B Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026